Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

dc.contributor.authorBilici, Ahmet
dc.contributor.authorOlmez, Omer Fatih
dc.contributor.authorSezer, Ahmet
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorCubukcu, Erdem
dc.date.accessioned2024-04-24T17:50:00Z
dc.date.available2024-04-24T17:50:00Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORKen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.description.sponsorshipRoche Pharmaceuticalsen_US
dc.description.sponsorshipRoche Pharmaceuticals.en_US
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16en_US
dc.identifier.urihttps://hdl.handle.net/11468/23147
dc.identifier.volume40en_US
dc.identifier.wosWOS:000863680302513
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleReal-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).en_US
dc.titleReal-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
dc.typeConference Objecten_US

Dosyalar